Nekton Capital Ltd. Takes $449,000 Position in Enfusion, Inc. (NYSE:ENFN)

Nekton Capital Ltd. bought a new position in shares of Enfusion, Inc. (NYSE:ENFN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 43,611 shares of the company's stock, valued at approximately $449,000. Enfusion comprises 1.2% of Nekton Capital Ltd.'s portfolio, making the stock its 7th largest position.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ENFN. KLP Kapitalforvaltning AS acquired a new position in shares of Enfusion during the fourth quarter valued at about $75,000. Tower Research Capital LLC TRC grew its stake in shares of Enfusion by 58.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 13,227 shares of the company's stock valued at $136,000 after purchasing an additional 4,889 shares during the period. Quantbot Technologies LP bought a new stake in shares of Enfusion in the 4th quarter valued at approximately $144,000. Intech Investment Management LLC acquired a new position in shares of Enfusion in the 4th quarter worth approximately $191,000. Finally, Wells Fargo & Company MN raised its holdings in shares of Enfusion by 46.8% in the 4th quarter. Wells Fargo & Company MN now owns 25,499 shares of the company's stock worth $263,000 after buying an additional 8,126 shares in the last quarter. Institutional investors and hedge funds own 81.05% of the company's stock.

Insider Activity

In other Enfusion news, CEO Oleg Movchan sold 2,790 shares of Enfusion stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $11.48, for a total value of $32,029.20. Following the transaction, the chief executive officer now owns 643,299 shares in the company, valued at $7,385,072.52. The trade was a 0.43 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Neal Pawar sold 14,560 shares of Enfusion stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $11.38, for a total value of $165,692.80. Following the completion of the transaction, the chief operating officer now owns 1,217,067 shares in the company, valued at approximately $13,850,222.46. This represents a 1.18 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 66,223 shares of company stock valued at $754,778. 36.44% of the stock is owned by insiders.

Enfusion Stock Performance

ENFN traded up $0.05 during mid-day trading on Friday, reaching $10.85. The stock had a trading volume of 2,461,878 shares, compared to its average volume of 640,409. The stock has a market capitalization of $1.40 billion, a P/E ratio of 271.29, a P/E/G ratio of 1.85 and a beta of 0.92. The firm's fifty day simple moving average is $11.06 and its two-hundred day simple moving average is $10.50. Enfusion, Inc. has a 52 week low of $7.83 and a 52 week high of $11.80.

Enfusion (NYSE:ENFN - Get Free Report) last posted its earnings results on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.02). Enfusion had a return on equity of 6.67% and a net margin of 1.70%. The business had revenue of $52.94 million for the quarter, compared to the consensus estimate of $53.98 million. As a group, analysts expect that Enfusion, Inc. will post 0.06 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, William Blair reissued a "market perform" rating on shares of Enfusion in a report on Monday, January 13th.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.